Ancestry wants your spit, your DNA and your trust. Should you give them all three?
By Stuart Leavenworth,
McClatchy DC Bureau [Cites CGS' Marcy Darnovsky]
| 05. 29. 2018
It markets its DNA kits with promises that tug at the heartstrings: Discover ancestors. Strengthen family ties. Understand your life.
Aided by venture capital and a flood of savvy marketing, Ancestry LLC has grown to become the world’s largest DNA testing conglomerate. Since 2012, it has lured more than 5 million people to spit into tubes and add their genetic code to the world’s largest private database of DNA. It has also banked away the world’s largest collection of human spittle, numbering in the hundreds of gallons.
In the age of Facebook and Google, consumers seem comfortable surrendering their personal information to corporations that aggregate it and monetize it. But Ancestry and other DNA testing companies have added an audacious tweak: Consumers are now paying to hand over their genetic code, their most sensitive individual identifier, to companies that could monetize it far into the future.
Ancestry officials say they have state-of-the-art systems to prevent hacking and security breaches. So far the company has sidestepped privacy scandals that tripped up companies like Facebook, which allowed a political data firm, Cambridge...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...